High-performance liquid chromatographic method for the bioequivalence evaluation of desloratadine fumarate tablets in dogs

被引:23
作者
Liu, LH
Qi, ML
Wang, P
Li, HZ
机构
[1] Beijing Inst Technol, Sch Chem Engn & Mat Sci, Dept Chem, Beijing 100081, Peoples R China
[2] Shenyang Pharmaceut Univ, Sch Pharm, Shenyang, Peoples R China
[3] Shenyang Pharmtech Inst Pharmaceut, Shenyang, Peoples R China
关键词
desloratadine fumarate; HPLC; bioequivalence;
D O I
10.1016/j.jpba.2003.11.002
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
A simple HPLC method was developed for the determination of desloratadine in dog plasma and was used for evaluating the bioequivalence of desloratadine fumarate tablets and desloratadine tablets in dogs. Chromatographic separation was performed on a Hypersil CN column (150 mm x 5.0 mm, 5 mum) using a mixture of methanol, acetonitrile and phosphate buffer (pH 5.5; 0.01 mol/l) (35:35:30, v/v/v) as mobile phase delivered at a flow rate of 0.8 ml/min. The detection was set at 241 nm. The limit of quantitation was 5.0 ng/ml. The calibration range was from 5.0 to 800.0 ng/ml. Inter- and intra-day precision ranged from 1.8 to 3.8% and from 2.2 to 9.0%, respectively. The recovery of desloratadine from dog plasma ranged from 78.8 to 82.0%. The developed method was applied to the bioequivalence studies of desloratadine fumarate tablets (test preparation) and desloratadine tablets (reference preparation) in five dogs. Pharmacokinetic parameters t(max), C-max, AUC(0-t), AUC(0-infinity), t(1/2) were determined from plasma concentration-time profiles of both preparations. The analysis of variance (ANOVA) did not show any significant difference between the two preparations and 90% confidence intervals fell within the acceptable range for bioequivalence. Based on these statistical inferences it was concluded that the two preparations exhibited comparable pharmacokinetic profiles and that desloratadine fumarate tablets was bioequivalent to desloratadine tablets. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:1013 / 1019
页数:7
相关论文
共 10 条
  • [1] *EUR COMM, 1991, INV BIOAV BIOEQ RUL, V3, P149
  • [2] Graul A., 2000, Drugs of the Future, V25, P339, DOI 10.1358/dof.2000.025.04.565303
  • [3] HANDLEY DA, 1997, ANN ALLERG ASTHMA IM, V78, P164
  • [4] PHARMACOKINETICS AND DOSE PROPORTIONALITY OF LORATADINE
    HILBERT, J
    RADWANSKI, E
    WEGLEIN, R
    LUC, V
    PERENTESIS, G
    SYMCHOWICZ, S
    ZAMPAGLIONE, N
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 27 (09) : 694 - 698
  • [5] SENSITIVE GAS-LIQUID-CHROMATOGRAPHIC METHOD FOR THE DETERMINATION OF LORATADINE AND ITS MAJOR ACTIVE METABOLITE, DESCARBOETHOXYLORATADINE, IN HUMAN PLASMA USING A NITROGEN-PHOSPHORUS DETECTOR
    JOHNSON, R
    CHRISTENSEN, J
    LIN, CC
    [J]. JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1994, 657 (01): : 125 - 131
  • [6] Sensitive liquid chromatography-tandem mass spectrometry method for the determination of loratadine and its major active metabolite descarboethoxyloratadine in human plasma
    Sutherland, FCW
    de Jager, AD
    Badenhorst, D
    Scanes, T
    Hundt, HKL
    Swart, KJ
    Hundt, AF
    [J]. JOURNAL OF CHROMATOGRAPHY A, 2001, 914 (1-2) : 37 - 43
  • [7] *WHO EXP COMM, 1995, WHO TECHN REP SER, V850
  • [8] [谢智勇 Xie Zhiyong], 2002, [中国临床药理学杂志, The Chinese Journal of Clinical Pharmacology], V18, P211
  • [9] Validation of a sensitive and automated 96-well solid-phase extraction liquid chromatography-tandem mass spectrometry method for the determination of desloratadine and 3-hydroxydesloratadine in human plasma
    Yang, LY
    Clement, RP
    Kantesaria, B
    Reyderman, L
    Beaudry, F
    Grandmaison, C
    Di Donato, L
    Masse, R
    Rudewicz, PJ
    [J]. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2003, 792 (02): : 229 - 240
  • [10] ZHONG D, 1994, PHARMAZIE, V49, P736